Healio Rheumatology—July 6, 2017
Healio Rheumatology interviewed Mary K. Crow, MD, physician-in-chief and chair of Rheumatology at HSS, about the future of lupus and the need for improved drug therapy.
Dr. Crow said better understanding about the molecular pathway and underlying mechanisms of lupus can lead to better therapy. "My own speculation is that we will probably end up with combination therapies and maybe combinations will allow us to use lower doses, each of one or two or three therapies to avoid toxicity," she said.
Read the full article at healio.com [registration required].
212.606.1197
mediarelations@hss.edu